Saturday, June 25, 2022

Clovis Oncology Inc. [CLVS] Rolfe Lindsey makes an insider sale of 2,650 shares worth 1703.0.

Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Clovis Oncology Inc. shares valued at $1,703 were sold by Rolfe Lindsey on Jun 02. At $0.64 per share, Rolfe Lindsey sold 2,650 shares. The insider’s holdings dropped to 103,016 shares worth approximately $0.16 million following the completion of this transaction.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Also, Harding Thomas C. sold 218 shares, netting a total of over 140 in proceeds. Following the sale of shares at $0.64 each, the insider now holds 3,225 shares.

Before that, Harding Thomas C. had sold 1,504 shares from its account. In a trade valued at $966, the insider traded Clovis Oncology Inc. shares for $0.64 each. Upon closing the transaction, the insider’s holdings decreased to 1,504 shares, worth approximately $22521.600000000002.

As published in a research note from H.C. Wainwright on May 06, 2022, Clovis Oncology Inc. [CLVS] has been rated down from a Buy to a Neutral. Analysts at H.C. Wainwright resumed the stock at ‘”a Buy”‘ outlook in a report released in mid May. As of April 27, 2020, SVB Leerink has decreased its “Mkt perform” rating to a “an Underperform” for CLVS. Earlier on April 09, 2020, BofA/Merrill downgraded its rating. Their new recommendation was “an Underperform” for CLVS stock which previously was a “a Neutral”.

Analyzing CLVS’s Price Performance

On Wednesday, Clovis Oncology Inc. [NASDAQ: CLVS] plunged -6.71% to $1.53. The stock’s lowest price that day was $1.47, but it reached a high of $1.84 in the same session. During the last five days, there has been a surge of approximately 88.89%. Over the course of the year, Clovis Oncology Inc. shares have dropped approximately -43.54%. Shares of the company reached a 52-week high of $3.1400 on 04/06/22 and a 52-week low of $0.5810 on 06/13/22. A 50-day SMA is recorded $1.2966, while a 200-day SMA reached $2.6052. Nevertheless, trading volume fell to 30.3 million shares from 110.21 million shares the previous day.

Support And Resistance Levels for Clovis Oncology Inc. (CLVS)

According to the 24-hour chart, there is a support level at 1.3867, which, if violated, would cause prices to drop to 1.2433. In the upper region, resistance lies at 1.7567. The next price resistance is at 1.9833. RSI (Relative Strength Index) is 67.23 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.5428, which suggests the price will decrease in the coming days. Percent R is at 47.83%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.

Which companies own the most shares of Clovis Oncology Inc. (CLVS)?

According to The Vanguard Group, Inc. filings, the company currently owns 12,073,240 shares, which is about 8.39% of the total CLVS shares outstanding. The investor’s shares have appreciated by 2,252,669 from its previous 13-F filing of 9820571.0 shares. With the completion of the buy, BlackRock Fund Advisors’s stake is now worth $5,938,800. Palo Alto Investors LP acquire a 11.91% interest valued at $3.11 million while Millennium Management LLC purchased a 2,525,471 stake. A total of -13,495,065 shares of Clovis Oncology Inc. were bought by SSgA Funds Management, Inc. during the quarter, and -115,914 were sold by Geode Capital Management LLC. In its current portfolio, Renaissance Technologies LLC holds 1,459,900 shares valued at $1.01 million.

In terms of Clovis Oncology Inc. share price expectations, FactSet research, analysts set an average price target of $3.00 in the next 12 months, up nearly 82.93% from the previous closing price of $1.64. Analysts anticipate Clovis Oncology Inc. stock to reach $3.00 by 2022, with the lowest price target being $3.00. In spite of this, 3 analysts ranked Clovis Oncology Inc. stock as a Hold at the end of 2022. On January 08, 2020, H.C. Wainwright assigned a price target of “a Buy” to the stock and reiterated coverage with a $27.

Latest news

Related news


Please enter your comment!
Please enter your name here




Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam